AI in drug discovery market to increase at CAGR of 40.8 percent
Research has found that artificial intelligence in drug discovery will be worth $1,434 million by the end of 2024.
List view / Grid view
Research has found that artificial intelligence in drug discovery will be worth $1,434 million by the end of 2024.
The CyBio FeliX pipetting system was used to perform all liquid handling steps of the library preparation workflow for personal genome analysis.
The imaging equipment, European XFEL, is said to mark a new age of protein movie-making and enables enzymes involved in disease to be observed in real-time.
A novel computational method has led to the discovery of genes whose alteration may contribute to cancer susceptibility and may lead to new therapeutic targets for cancers.
Researchers in Australia and the US have launched the first open-source database detailing genetic variants that impact human health and disease.
New software has been developed that can reveal the detailed RNA-binding properties of proteins, which is important for characterising the pathology of many diseases.
A machine-learning algorithm has been created that automates high-throughput screens of epigenetic medicines.
A drug discovery platform for mental health treatment could also help to identify mechanisms for the treatment of substance use disorders.
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
New protein-painting technology could lead to developing cancer immunotherapy medicines that can be administered as a pill.
A new platform brings together genome editing with magnetic cell sorting to reveal new drug targets for cancer and regenerative medicine.
A new platform combines AI, flow chemistry and robotics to minimise the need for human intervention in the synthesis process.
The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
Upstream bioprocessing is the epicentre of biologics development, wherein scientists piece together a series of carefully chosen processes with contributing components and parameters to enable the production of highly effective biotherapeutics. Unjulie Bhanot explains why an effective data management system is vital in this quest for the next big therapeutic.